Malta - Ingliż - Malta Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefuroxime - powder for solution for injection powder for suspension for injection - cefuroxime 250 mg - antibacterials for systemic use

Iżrael - Ingliż - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution for inj/inf - cefuroxime as sodium salt 1500 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis

Stati Uniti - Ingliż - NLM (National Library of Medicine)

hospira, inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime for injection and other antibacterial drugs, cefuroxime for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. cefuroxime for injection has been used successfully in these mixed infections in which several organisms have been isolated. in certai

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cefuroxime sodium - powder for solution for injection/infusion - 1.5 gram(s) - second-generation cephalosporins; cefuroxime

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 1.5 gram(s) - second-generation cephalosporins; cefuroxime

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;  ;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic arthritis. - obstetric and gynaecological infections, pelvic inflammatory diseases. - gonorrhoea particularly when penicillin is unsuitable. - other infections including septicaemia, meningitis and peritonitis. - prophylaxis against infection in abdominal, pelvic, orthopaedic, cardiac, pulmonary, oesophageal and vascular surgery where there is increased risk from infection.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection/infusion - 1500 milligram(s) - second-generation cephalosporins; cefuroxime

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection - 250 milligram(s) - second-generation cephalosporins; cefuroxime